John Richard White - Coatesville PA Louis Martin Pelus - Richboro PA
Assignee:
Human Genome Sciences, Inc. - Rockville MD
International Classification:
A61K 3819
US Classification:
424 851, 514 2, 514 8, 514 12
Abstract:
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine -4 or a biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
A method of mobilizing hematopoietic stem cells from the bone marrow to the peripheral circulation is provided by administering to an animal an effective amount of mature, modified or multimeric forms of KC, gro, gro, or gro.
John White - Coatesville PA, US Louis Pelus - Richboro PA, US
Assignee:
Smithkline Beecham Corporation
International Classification:
A61K038/19 A61K031/545
US Classification:
424/085100, 514/200000
Abstract:
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
Method Of Treating Sepsis And Ards Using Chemokine Beta-6
John White - Coatesville PA, US Louis Pelus - Richboro PA, US
International Classification:
A61K038/19 A61K031/545
US Classification:
424/085100, 514/200000
Abstract:
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
Method Of Treating Sepsis And Ards Using Chemokine Beta-9
John White - Coatesville PA, US Louis Pelus - Richboro PA, US
Assignee:
Smithkline Beecham Corporation
International Classification:
A61K038/19 A61K031/545
US Classification:
424/085100, 514/200000
Abstract:
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
The present invention provides method of increasing the biological activity of KC, gro-, gro-, and gro- proteins, truncated and modified proteins characterized by having biological activity at least 1 log better than the full-length protein, and pharmaceutical compositions containing same.